- Home
- HOOK
HOOK
HOOKIPA Pharma Inc.
as 07-26-2024 4:00pm EST
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 61.8M | IPO Year: | 2019 |
| Target Price: | $43.25 | AVG Volume (30 days): | 56.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.10 - $11.30 | Next Earning Date: | 08-08-2024 |
| Revenue: | $53,552,000 | Revenue Growth: | 235.12% |
| Revenue Growth (this year): | 172.7% | Revenue Growth (next year): | -65.72% |
Latest HOOKIPA Pharma Inc. News
HOOK Breaking Stock News: Dive into HOOK Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO
GlobeNewswire
4 days ago
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
GlobeNewswire
19 days ago
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
Clinical Trials Arena
25 days ago
HOOKIPA Pharma doses first subject in Phase Ib HIV treatment trial
MT Newswires
25 days ago
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study
GlobeNewswire
25 days ago
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
Compare HOOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HOOK HOOKIPA Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.